{"html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fwww.shawshanklife.com%2Fentry%2F2018%2F11%2F23%2F034640\" title=\"\u8a18\u4e8b\uff1a\u6c7a\u7b97\u8aac\u660e\u4f1a\u8cc7\u6599\u306b\u3064\u3044\u3066(\u88dc\u8db3) - \u30d6\u30e9\u30a4\u30c8\u30d1\u30b9\u30fb\u30b9\u30c8\u30fc\u30ea\u30fc\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","blog_url":"https://www.shawshanklife.com/","height":"190","author_url":"https://blog.hatena.ne.jp/SHAWSHANKlife/","title":"\u8a18\u4e8b\uff1a\u6c7a\u7b97\u8aac\u660e\u4f1a\u8cc7\u6599\u306b\u3064\u3044\u3066(\u88dc\u8db3)","author_name":"SHAWSHANKlife","blog_title":"\u30d6\u30e9\u30a4\u30c8\u30d1\u30b9\u30fb\u30b9\u30c8\u30fc\u30ea\u30fc","url":"https://www.shawshanklife.com/entry/2018/11/23/034640","type":"rich","provider_name":"Hatena Blog","width":"100%","version":"1.0","image_url":null,"categories":[],"provider_url":"https://hatena.blog","description":"\u8a18\u4e8b\u2192\u6c7a\u7b97\u8aac\u660e\u4f1a\u8cc7\u6599\u306b\u3064\u3044\u3066\u3001\u4ee5\u4e0b\u88dc\u8db3\u3057\u3066\u304a\u304d\u307e\u3059\u3002GRN-1201(\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093)\u30ad\u30fc\u30c8\u30eb\u30fc\u30c0\u3068\u306e\u4f75\u7528\u3001\u7b2c\u2161\u30d5\u30a7\u30fc\u30ba\u306b\u3064\u3044\u30661\u3001\u6cbb\u9a13\u540d\u306e\u5909\u66f4GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC\u304cA Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN- 1201 Added to Pembrolizumab in Subjects with Non-Small Cell Lung Cancer with High PD-L1 Expression\u306b\u2026","published":"2018-11-23 03:46:40"}